Walk Test
Lung function ‘stable’ 3 years after hematopoietic cell transplant in sickle cell disease
Patients with sickle cell disease who had non-myeloablative hematopoietic cell transplants had similar or better lung function 3 years later, according to results published in Annals of the American Thoracic Society.
Lung abnormalities persist in 36% of individuals 3 years after COVID-19 hospitalization
Three years after hospital discharge for COVID-19, 36% of individuals still had residual lung abnormalities, according to results published in European Respiratory Journal.
Combination macitentan, tadalafil tablet improves exercise capacity in PAH
SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.
Endurance, respiratory symptom burden improve 1 year after COVID-19 hospitalization
WASHINGTON — One year after COVID-19 hospitalization, measures of endurance and respiratory symptom burden improved, according to an abstract presented at the American Thoracic Society International Conference.
Inhaled seralutinib lowers pulmonary vascular resistance in adults with PAH over 24 weeks
WASHINGTON — In adults with pulmonary arterial hypertension, seralutinib reduced pulmonary vascular resistance over 24 weeks, according to a presentation at the American Thoracic Society International Conference.
Chest sensors allow remote 6-minute walk testing for patients with pulmonary hypertension
Chest sensors that measured heart rate and accelerometry enabled patients with pulmonary artery hypertension to undergo 6-minute walk tests remotely with similar data as those collected in clinic, according to study results in CHEST.
Low physical function in older adults predictive of worse CVD outcomes
Poor physical function was associated with increased risk for CHD, stroke and HF in adults older than 65 years, according to a new analysis of the Atherosclerosis Risk in Communities study.
Patisiran meets primary endpoint in trial for ATTR amyloidosis, cardiomyopathy
Alnylam announced top-line results of a trial showing that patisiran improved 6-minute walk test distance in patients with transthyretin-mediated amyloidosis and cardiomyopathy.
Data acquired from Apple devices may aid in monitoring frailty in patients with CVD
Data acquired from iPhones and Apple Watches successfully predicted 6-minute walk test results and may be beneficial in monitoring frailty in patients with CVD, according to results published in PLOS ONE.
Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH
New exploratory endpoint data from the INSPIRE study show improvements after 2 months of treatment with inhaled treprostinil in quality of life, 6-minute walk distance and New York Heart Association functional class.